Conventional tests for prostate cancer diagnoses using PSA are mainly performed in centralized laboratories using large-scale automated analyzers, and the associated medical costs increase due to various reasons, such as sample transport, increased waiting time, and simple management. This evidence concerns the gene KLK3 and Familial prostate cancer.